Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Study Summary

The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide FDC in adolescents and children with HIV-1.

Conditions

HIV-1 Infection

Interventions / Drugs

B/F/TAF (Adult Strength)B/F/TAF (Low Dose)B/F/TAF (TOS)B/F/TAF (TOS)B/F/TAF (TOS)B/F/TAF (TOS)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment177 participants

Primary Completion—

Lead SponsorGilead Sciences

Data Retrieved2026-04-11 02:55:27.112867+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.